APA (7th ed.) Citation

Sabatine, M. S., Leiter, L. A., Wiviott, S. D., Giugliano, R. P., Deedwania, P., De Ferrari, G. M., . . . Pedersen, T. R. (2017). Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: A prespecified analysis of the FOURIER randomised controlled trial. The lancet. Diabetes & endocrinology, 5(12), 941. https://doi.org/10.1016/S2213-8587(17)30313-3

Chicago Style (17th ed.) Citation

Sabatine, Marc S., et al. "Cardiovascular Safety and Efficacy of the PCSK9 Inhibitor Evolocumab in Patients with and Without Diabetes and the Effect of Evolocumab on Glycaemia and Risk of New-onset Diabetes: A Prespecified Analysis of the FOURIER Randomised Controlled Trial." The Lancet. Diabetes & Endocrinology 5, no. 12 (2017): 941. https://doi.org/10.1016/S2213-8587(17)30313-3.

MLA (9th ed.) Citation

Sabatine, Marc S., et al. "Cardiovascular Safety and Efficacy of the PCSK9 Inhibitor Evolocumab in Patients with and Without Diabetes and the Effect of Evolocumab on Glycaemia and Risk of New-onset Diabetes: A Prespecified Analysis of the FOURIER Randomised Controlled Trial." The Lancet. Diabetes & Endocrinology, vol. 5, no. 12, 2017, p. 941, https://doi.org/10.1016/S2213-8587(17)30313-3.